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Abstract  23 
Introduction Patients with SDHx mutations need long-term radiological surveillance for the 24 
development of paragangliomas and phaeochromocytomas, but no longitudinal data exist. We 25 
assessed the performance of rapid-sequence non-contrast magnetic resonance imaging (MRI) in the 26 
long-term monitoring of patients with SDHx mutations. 27 
Methods Retrospective study between 2005-2015 at a University Hospital and regional endocrine 28 
genetics referral center. Clinical and imaging data of forty-seven patients with SDHx mutations 29 
[SDHB (36), SDHC (6), SDHD (5)] who had surveillance for detection of paragangliomas by rapid-30 
sequence non-contrast MRI (base of skull to pubic symphysis) were collected. 31 
Results Twelve index cases (9 SDHB, 1 SDHC, 2 SDHD) and 35 mutation-positive relatives were 32 
monitored for a mean of 6.4 years (range 3.1 to 10.0 years). Mean age at the end of the study: SDHB 33 
46.9+/-17.6 years; SDHC 42.3+/-24.4 years; SDHD 54.9 +/- 10.6 years. Excluding imaging at initial 34 
diagnosis of index cases forty-three patients underwent 116 rapid-sequence MRI scans: 83 scans 35 
were negative and 31 scans were positive for a sPGL/HNPGL in 13 patients. Most patients had 36 
multiple scans [n=number of patients (number of rapid-sequence MRI scans during screening)]; n=9 37 
(2), n=20 (3), n=6 (4), n=1 (6). Nine patients (3 index) were diagnosed with new paragangliomas 38 
during surveillance and non-operated tumour size was monitored in 9 patients. There were two false 39 
positive scans (1.6%). Scans were repeated every 27 +/- 9 months.  40 
Conclusions Biannual rapid-sequence non-contrast MRI is effective to monitor patients with SDHx 41 
mutations for detection of new tumours and monitoring of known tumours. 42 
 43 
 44 
 45 
 3 
Introduction 46 
Germ-line mutations of the subunits of the mitochondrial complex II enzyme succinate 47 
dehydrogenase (SDHA, SDHB, SDHC, SDHD and SDHAF2), SDHx, are associated with familial 48 
paraganglioma (PGL) of the sympathetic chain (sPGL), the parasympathetic chain of the head and 49 
neck (HNPGL), and adrenal phaeochromocytoma 
1-4
. In general most phaeochromocytomas secrete 50 
catecholamines, whereas sPGLs may be functional or non-secretory, and HNPGLs are usually 51 
biochemically silent 
5
.  52 
 53 
SDHx are tumour suppressor genes, characterized by loss of heterozygosity in tumour cells due to 54 
somatic mutations or loss of expression of the wild type allele 
6, 7
. The underlying mechanism of 55 
tumorigenesis in SDHx mutations is still unclear, but non-hypoxic HIF-1alpha and HIF-2alpha 56 
activation is a key feature in pathogenesis  ? ?ƉƐĞƵĚŽŚǇƉŽǆŝĂ ?ŚǇƉŽƚŚĞƐŝƐ ? 8. In SDHx-related 57 
tumorigenesis there is loss of SDH enzymatic activity and intracellular accumulation of succinate 58 
leading to inhibition of prolyl-hydroxylases that usually degrade HIF-1alpha 
9-11
. HIF-1alpha is then 59 
able to translocate to the nucleus and activate gene expression promoting angiogenesis, cell survival, 60 
and glycolysis 
10
. The role of oxygen-sensing pathways in SDHx tumorigenesis is also supported by 61 
observations linking living at high-altitude and an increase in disease prevalence and phenotypic 62 
severity 
12, 13
. 63 
 64 
Patients with SDHx mutations are at life-long risk of multifocal, recurrent and malignant PGLs. 65 
Mutations in the different subunits cause specific patterns of disease: individuals with paternally-66 
inherited SDHD mutations are more likely to develop HNPGL, multifocal disease, and less frequently 67 
sPGLs 
2, 5, 14, 15
; SDHB mutation carriers may develop sPGLs that have a higher malignant potential 68 
compared with sporadic or other syndromic PGLs 
1, 14
; SDHC mutations are rare, with affected 69 
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 4 
individuals developing HNPGL and phaeochromocytoma that have a low risk of malignancy. 70 
Penetrance may occur over the life course, but is incomplete and variable: some SDHx members of 71 
the same family experience either no tumour development, or a benign or asymptomatic course, 72 
whilst others develop devastating and aggressive disease. This underscores the need for appropriate 73 
biochemical and imaging screening strategies that may be used in an affected individual over their 74 
whole life to detect tumour development, since the primary treatment is resection by an expert 75 
surgeon and where better outcomes are found when tumours are detected early 
16
.   76 
 77 
Genetic testing for SDHx mutations has been available for approximately the last decade. Although it 78 
is widely accepted that carriers of SDHx mutations should be monitored for the penetrance of 79 
disease, there are no studies reporting the outcome of longitudinal monitoring as highlighted in 80 
recently published clinical practice guidelines 
17
.  Therefore, we report our longitudinal 10-year 81 
experience of surveillance imaging in a large cohort of SDHx patients attending our dedicated 82 
endocrine genetics clinic at a University Hospital using rapid sequence non-contrast magnetic 83 
resonance imaging (MRI) as a non-ionizing imaging modality appropriate for life-long follow-up to 84 
address three key clinical questions: 1), does this MRI technique detect new tumours in patients 85 
with SDHx?; 2), can this MRI technique be used to monitor size and extent of known disease in 86 
patients in whom definitive surgical excision has not taken place because of tumour site or patient 87 
preference?; 3), what is an appropriate time interval between imaging studies? 88 
 89 
 90 
 91 
 92 
 5 
 93 
Methods 94 
Patients 95 
The study was approved as a case notes review by our institutional review board (ID number 3861).  96 
All patients with pathogenic SDHx mutations (n=47) attending the dedicated Endocrine Genetics 97 
clinic at the Royal Hallamshire Hospital, Sheffield Teaching Hospitals (STH) NHS Foundation Trust, a 98 
regional referral center, from October 2005 to May 2015, were included. A retrospective review of 99 
the medical notes, imaging and biochemistry was conducted. All patients have been reviewed at 100 
each clinic visit by one experienced clinician (JNP). All index cases had either excision of their 101 
presenting tumour or other treatment prior to embarking on surveillance, and the data presented 102 
here on imaging are all from the surveillance programme. All mutation-positive relatives had the first 103 
surveillance imaging following genetic diagnosis and all their imaging tests are included in the data 104 
presented here.  105 
At our institution genetic testing is performed on patients with phaeochromocytoma aged <50 years 106 
or a family history suggesting possible genetically driven disease (such as early cardiac death), or in 107 
any patient presenting with sPGL or HNPGL. Genetic testing was performed at the accredited 108 
regional genetics laboratory as part of the National Genetics Service of the National Health Service, 109 
UK. Carriers of SDHD mutations were offered the screening programme if the mutation was of 110 
paternal origin as it is well-documented that only those inheriting an SDHD mutation from their 111 
father exhibit clinical manifestations of the syndrome 
3
.  112 
All data were discussed at the weekly endocrine multidisciplinary team meeting in the presence of 113 
an endocrine radiologist, endocrinologists, endocrine surgeons and chemical pathologists, with the 114 
outcome of the studies documented as negative (normal screening), positive (paraganglioma 115 
present) or requiring further investigations. As there is no gold standard imaging modality that can 116 
 6 
be used for long-term surveillance, i.e. without significant radiation exposure and multiple tests, the 117 
outcome of this discussion for each scan was collected and analysed. The outcome of a scan was 118 
considered false positive if the lesion was not confirmed to be a paraganglioma at subsequent 119 
imaging.  120 
 121 
Surveillance protocol 122 
At baseline a detailed clinical assessment was made of all newly referred patients, including a 123 
detailed clinical history, clinical examination, together with radiological and biochemical 124 
investigations. Thereafter, patients were seen approximately yearly for clinical evaluation and 125 
biochemical testing (two 24-hour collections of urinary fractionated metanephrines measured by 126 
high-performance liquid chromatography from 2005-2010 or free plasma metanephrines measured 127 
by liquid chromatography-tandem mass spectrometry, since 2010) with radiological evaluation every 128 
2 years. For those with disease detected or lesions that require further characterization further 129 
imaging evaluation and clinical assessments were made on an individualized basis. 130 
 131 
Imaging 132 
MR images were acquired from skull base to the pubic symphysis, including all sympathetic and 133 
parasympathetic ganglia, on a 1.5T Siemens Avanto scanner (Siemens AG Munich) and subsequently 134 
reviewed by a single expert endocrine radiologist (MB). The imaging protocol is based on three rapid, 135 
unenhanced, non-high definition sequences (Transverse T1 spin echo in/out phase, Transverse and 136 
Coronal T2 Haste). The combination of both T1 and T2-weighted images in two planes gives a survey 137 
from skull base to pelvis.  Dedicated neck and phased array body coils were used.  Parameters for 138 
neck imaging; T2 5mm thickness with 1mm slice gap TR 3650ms TE 99ms matrix size 320x70, T1 139 
5mm thickness with 1mm slice gap TR 611ms TE 12ms matrix size 320x70. Parameters for chest, 140 
 7 
abdomen and pelvis imaging; breath hold sequences T2 Haste 7mm with 1mm slice gap TR 1100ms 141 
TE 92ms matrix size 256x80, T1 gradient echo 8mm thickness with 1mm slice gap TR 249ms TE 142 
2.29ms (out of phase) 4.76ms (in phase). Each sequence takes usually 2-3 minutes and the average 143 
sized patient requires this to be done in three blocks. There is no requirement for intravenous 144 
contrast in the surveillance scans and the total duration of imaging is 25 to 30 minutes. 145 
Paragangliomas and phaeochromocytomas have high signal on T2-weighted images. The same 146 
protocol was used for all patients regardless of causative mutation.  147 
 148 
Statistics 149 
Statistical analysis was performed using one-way ANOVA (GraphPad prism 6.0). Results are reported 150 
as mean values +/- one standard deviation. A p-value of less than 0.05 was considered significant.  151 
 152 
Results 153 
Patients 154 
Forty-seven patients with SDHx mutations were included: 36 patients with an SDHB mutation, 6 with 155 
an SDHC mutation, and 5 with an SDHD mutation. Twelve out of 47 patients were index cases (9 156 
SDHB, 1 SDHC, 2 SDHD); the remaining 35 patients were gene-positive relatives. Two patients died 157 
during the study, one from complications of metastatic sPGL and one from an unrelated cause. At 158 
the end of the screening period, defined as the time of death (n=2) or May 2015 (n=45), there was 159 
no difference in the mean age between patients with different SDH subunit mutations (SDHB 46.9+/-160 
17.6 years, SDHC 42.3+/-24.4 years, SDHD 54.9+/-10.6 years, p=0.5), (this lack of difference may be 161 
due to lack of power) (Table 1). There were seven different SDHB mutations, 1 SDHC and 2 different 162 
SDHD mutations. Mean duration of monitoring for all patients was 6.4 years (range 3.1-10.0 years).  163 
 8 
 164 
Overall, at any time eighteen patients (12 index cases and 6 screened relatives) developed a tumour 165 
either sPGL or HNPGL [SDHB 31% (11/36), SDHC 33% (2/6), SDHD 100% (5/5)] (Table 1 and Table 2). 166 
Patients with SDHB mutations predominantly developed sPGLs. Patients with SDHD mutations 167 
exclusively developed HNPGLs (5/ 5 patients) and had multifocal disease (5/ 5) (Table 2). The 168 
youngest age at first presentation was 12y (SDHD) and 15y (SDHB). At the time of diagnosis of the 169 
first tumour the median age was [all patients (index)]; SDHB 28yo (28yo), SDHD 31yo (31yo). 170 
 171 
Rapid-sequence MRI surveillance 172 
Forty-three out of 47 patients underwent surveillance imaging with rapid-sequence MRI including all 173 
12 index patients; four patients did not have MRI scans due to severe claustrophobia or non-174 
attendance, were imaged by CT and are excluded from the analysis.  Excluding any imaging 175 
performed during the diagnosis of the index tumours, imaging was performed on the surveillance 176 
protocol in the remaining 43 patients who underwent 116 rapid-sequence MRI scans: 83 scans were 177 
negative for sPGL/HNPGL and 31 were positive in 13 patients (Figure 1).  At the end of the study 178 
there were no cases of missed PGLs, i.e. in patients who developed tumours after the first 179 
surveillance MRI (n=4; 2 noradrenaline-secreting sPGLs, 1 HNPGL confirmed with US, 1 thoracic non-180 
secreting sPGL confirmed with dedicated MRI imaging), none of the tumours were found to be 181 
present on re-review of earlier imaging. A number of radiological tests were performed in patients 182 
who had a positive MRI either for further characterization of positive findings or for disease 183 
monitoring [CT (8 scans from 6 patients), USS neck (15 scans from 6 patients), MIBG (4) and 
18
FDG 184 
PET CT (8)] (Table 3). USS neck was used to monitor size of HNPGLs.  Rapid-sequence MRI screening 185 
was repeated every 27 +/- 9 months (median 25 months) and the majority of patients had more than 186 
one scan during surveillance [n=number of patients (number of rapid-sequence MRI scans during 187 
Formatted: Not Highlight
Formatted: Not Highlight
Formatted: Not Highlight
Formatted: Not Highlight
 9 
surveillance)]; n=9 (2), n=20 (3), n=6 (4), n=1 (6). The maximum diameter of new tumours diagnosed 188 
during surveillance with rapid-sequence MRI ranged between 0.6 to 3.5cm, with no differences in 189 
imaging characteristics between SDHB, SDHC and SDHD subunit mutations. 190 
 191 
Index cases (Table 2, Figure 2) 192 
Six out of 12 index patients had complete surgical resection of sPGLs (all noradrenaline-secreting) 193 
confirmed with histology prior to this study, normal biochemistry and a negative initial rapid-194 
sequence MRI scan at surveillance baseline. Two patients (SDHB) were diagnosed with new sPGLs at 195 
the 2
nd
 surveillance MRI (noradrenaline-secreting) and were referred for surgical treatment.  196 
Four index cases with non-metastatic PGLs were not tumour-free on embarking on surveillance 197 
[subtotal resection due to multiple HNPGLs/ extensive disease (n=3, patients 12, 14, 16) or non-198 
resected disease (n=1, patient 9)]. The rapid sequence MRI was used to follow the size of tumours 199 
and detect new disease in this group of patients; one patient developed progressive disease and was 200 
referred for surgery (patient 12), 2 patients with HNPGLs (glomus jugulare) showed slow increase of 201 
the tumours and referred for radiosurgery (patients 14, 16), and 1 patient has stable disease (patient 202 
9, sPGL).  203 
There has been histological confirmation of sPGL/HNPGL in all patients who had surgical treatment 204 
and in one patient with metastatic disease who had a biopsy (n=10).  Although histological 205 
confirmation was not made in two other patients, one has a functioning sPGL with characteristic 206 
imaging features and diagnostic biochemistry (patient 9) and one patient has a large glomus jugulare 207 
tumour with typical radiological features that has been treated with radiosurgery (patient 15). In 208 
each case surgical treatment was either refused by the patient, or not appropriate, respectively.  209 
 210 
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Genetically screened relatives (Table 2, Figure 2)   211 
During surveillance six genetically screened relatives were diagnosed with either a solitary (n=4) or 212 
multiple (n=2) paraganglioma(s) on rapid-sequence MRI. The majority of patients (5/6) were 213 
diagnosed with PGLs during their first MRI scan (patients 7, 13, 15, 17, 18). All tumours were non-214 
functioning and there was confirmation from histology (patient 7) or additional dedicated imaging.  215 
Except from one patient  who underwent surgical excision (patient 7), the tumours were not 216 
resected in the remaining four because of the anatomical position and subsequent MRI scans were 217 
used to monitor size and plan management (see below). In one patient (patient 8) a small 218 
(0.6x1.2cm) thoracic non-functioning sPGL was demonstrated at the 2
nd
 surveillance MRI, 28 months 219 
after an initial negative scan. The size of this tumour was also monitored by rapid-sequence MRIs 220 
due to the patient not wanting surgical intervention. 221 
Histological confirmation of a PGL has been made in all genetically screened relatives that had 222 
resection in whom the rapid sequence MRI was deemed consistent with a PGL (n=5). There are two 223 
patients with small thoracic non-secreting PGLs who have not had surgery (patients 8 and 13, see 224 
bellow). The diagnosis of sPGL in these patients is based on typical MRI features; FDG-PET was 225 
positive in one patient and negative on the second.  226 
 227 
Treatment 228 
Surgical treatment was offered to all patients with non-metastatic sPGL (n=10 patients that 229 
developed 12 sPGLs). Overall, 9 sPGLs were excised in 7 patients (all SDHB), one patient with 230 
metastatic disease (SDHB) was treated with chemotherapy and radiotherapy (patient 10), and in 231 
three patients the disease is monitored with imaging and biochemistry (2 SDHB, 1 SDHC; patients 8, 232 
9, and 13) (Table 2), with strong patient preference the reason for monitoring instead of surgical 233 
treatment; in two patients with non-secreting thoracic sPGLs (patients 8 and 13) this decision was 234 
Formatted: Not Highlight
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influenced by the high surgical risk due to the presence of co-morbidities and the anatomical 235 
challenges of surgery. There were nine carotid body (CB) tumours in five patients; four patients were 236 
managed conservatively with imaging to assess tumour size because of previous surgery for a 237 
contralateral CB tumour (n=3, SDHD) and patient preference (n=1, SDHD). Five patients with glomus 238 
jugulare tumours (4 index cases) were treated with gamma knife stereotactic radiosurgery (1 SDHB, 239 
1 SDHC, 3 SDHD; patients 3, 12, 14, 15, 16). One patient with a noradrenaline-secreting glomus 240 
tumour causing local pressure symptoms had gamma knife stereotactic surgery as surgical 241 
intervention was considered high risk (patient 3). Following treatment there was a gradual decrease 242 
in the level of catecholamines, with symptoms improved and imaging which showed reduction in 243 
tumour size within 2 years of intervention. A second patient (patient 12, SDHC mutation) with a large, 244 
HNPGL with intracranial extension was treated with a combination of tumour embolization, surgical 245 
resection, and radiosurgery to a small bone remnant. Three patients (patients 14, 15, 16) with 246 
multifocal HNPGLs had imaging surveillance followed by gamma knife therapy when an increase in 247 
tumour size was detected. Overall, gamma knife therapy led to growth arrest in 4/5 cases and 248 
tumour volume reduction in 1/5 and no complications from this intervention in up to five years of 249 
follow up. 250 
 251 
 252 
Pituitary adenomas 253 
The pituitary gland was included in the screening rapid sequence MRI. There were no 254 
macroadenomas detected but 2/43 patients were found to have a small pituitary abnormality, and 255 
underwent dedicated pituitary imaging revealing microadenomas: both patients carried the SDHB 256 
mutation c.379dupA [12% (2/17) of carriers in the cohort] aged 67 and 68. In both cases pituitary 257 
function was normal and there was no requirement for specific treatment. 258 
 12 
Twenty-two patients were found to have incidental findings on MRI during the screening period. 259 
Three patients required a referral for a specialist opinion (respiratory physicians for a lung nodule, 260 
gynecologist for an ovarian cyst and breast surgeons), 5 patients had further imaging for 261 
characterization of a benign incidental finding, and 14 patients required no further investigations. 262 
Two rapid-sequence MRI scans were characterized as false positive based on subsequent imaging; 263 
both cases were investigated by dedicated imaging (neck US or MR) that confirmed a lymphangioma 264 
and scar tissue, respectively.   265 
 266 
 267 
Discussion 268 
An increasing number of patients presenting with paragangliomas are being diagnosed with SDHx 269 
mutations since genetic testing became standard clinical practice, and need surveillance 
18
, to 270 
identify tumours at an early stage when they are amenable to surgical treatment and cure 
16
. Since 271 
malignant tumours have been described in children and adolescents, it is common clinical practice to 272 
offer genetic testing to relatives of affected individuals from around the second decade of life, with 273 
mutation carriers then being offered clinical, radiological and biochemical screening 
15, 19
. For such 274 
life-long screening it is, therefore, important to minimize cumulative radiation exposure. Recent 275 
clinical guidelines emphasize the need for surveillance 
17, 20
.  Our data support the use of rapid 276 
sequence MRI for this purpose. 277 
 278 
The clinical spectrum of paragangliomas is diverse. Without a clinical screening programme, 279 
mutation carriers are at risk of presenting late with complications of syndromes relating to 280 
catecholamine excess, local pressure effects of tumours and malignant and metastatic disease 
21
. 281 
Most tumours are, however, non-functioning and therefore biochemical and clinical monitoring 282 
 13 
alone is not enough.  Measurement of free plasma metanephrines has been reported to be the most 283 
sensitive test for functional paragangliomas and phaeochromocytomas 
22
 combined with the 284 
measurement of the dopamine metabolite 3-methoxytyramine since some paragangliomas produce 285 
only dopamine (Table 2) 
23
.  For these reasons our surveillance protocol mandates yearly 286 
biochemical and clinical assessment. 287 
 288 
There is a debate as to the gold standard for the detection of paragangliomas. A recent large French 289 
series of SDHx mutation carriers showed that a combination of imaging modalities (body CT, Head 290 
and neck MRA and octreotide scintigraphy) was 99% sensitive for paraganglioma detection 
24
; a sub-291 
analysis of the MRA scans from this study showed that a simplified shorter angio-MRI protocol had 292 
similar diagnostic performance to the full imaging protocol and could be used instead for the 293 
detection of HNPGLs 
25
.  Although CT has an excellent sensitivity, it involves the use of ionizing 294 
radiation and is not ideal for life-long surveillance.  MRI does not involve ionizing radiation and is 295 
acceptable for use in younger patients and females of reproductive age, making it an ideal 296 
surveillance imaging modality for individuals with SDHx mutations. Shorter scanning protocols to 297 
reduce scanning time of whole body MRI have been developed and cross-sectional data show these 298 
to be effective in this clinical setting 
26
. Functional imaging can further characterize any tumour, and 299 
assess for multifocal or metastatic disease 
27
.  In this context 
18
F-FDG PET has been used for several 300 
years in patients with SDHB mutations and metastatic disease 
28
, but recently 
68
Ga-DOTATATE 301 
PET/CT has been shown to be superior 
29
. Other compounds such as 
18
F-fluorodopamine (
18
F-FDA) 302 
and 
18
F-fluoro-dihydroxyphenylalanine (
18
F-FDOPA) have great promise but are not currently widely 303 
available 
30
. Although 
123
MIBG imaging is less sensitive than these modalities it offers a therapeutic 304 
option (
131
MIBG) in MIBG-avid patients with metastatic disease 
28, 31
. 305 
 306 
 14 
Our rapid MRI sequences minimizes time (skull base to symphysis pubis scanned in less than half an 307 
hour), cost (intravenous gadolinium contrast is not used) and provides accurate results; we have not 308 
identified a missed case of a paraganglioma using this rapid sequence MRI for ten years. 309 
Furthermore, our data show that this technique can be used reliably to detect new tumours as well 310 
as monitor tumour growth in patients managed conservatively. Because the majority of tumours 311 
detected in our cohort were on first screening of mutation carriers, we suggest that all index case-312 
relatives with a positive genetic test are offered imaging at the earliest opportunity, as this is the 313 
most likely time that tumours will be detected.  For patients who had negative initial screening use 314 
of rapid sequence MRI approximately every two years appears to be effective and clinically safe.  315 
Patients with known tumours under surveillance should have individualized follow-up.  An 316 
association of pituitary tumours and SDHx has been proposed 
32
, and our MRI protocol allows 317 
detection of pituitary tumours of size significant enough to pose a clinical management discussion.  318 
Other than the likelihood of the anatomic location of tumours, we found no differences in the MRI 319 
features of tumours due to SDHB, SDHC, or SDHD mutations.  320 
 321 
Gamma knife radiosurgery appears to be an effective treatment option for some patients with 322 
HNPGLs where surgery would carry too much morbidity, including those with a previous history of 323 
neck surgery (where the predicted postoperative neurological complications are significant) and 324 
older patients with significant perioperative risk 
33
. Whilst we report good outcomes from gamma 325 
knife radiosurgery it is important to note that we are the National Centre for Stereotactic 326 
radiosurgery and have treated more than 15,000 patients with this technique; it is likely that this 327 
high level of expertise had a positive impact on our patient outcomes, and good outcomes and low 328 
complications are reported from other high volume centers 
34
.  329 
 330 
 15 
The strengths of this study are that it is a single-center study at a center with extensive relevant 331 
imaging and clinical expertise, where a practical rapid sequence MRI imaging protocol has been 332 
developed and used for screening for over 10 years, with all cases routinely discussed in 333 
multidisciplinary meetings in the presence of endocrine surgeons and input from all specialists 334 
informed management decisions. Although small tumours (<5mm) may suffer from partial volume 335 
effects limiting interpretation the likelihood of tumours of this size causing a clinical syndrome 336 
associated with catecholamine excess or being of malignant potential, is low. Limitations of our 337 
study include the need for multidisciplinary expertise. Although this is a large cohort, the numbers of 338 
patients with positive scans remains small precluding statistical comparisons. Furthermore, a single 339 
gold standard test that can be used for long-term screening in these patients ĚŽĞƐŶ ?ƚĞǆŝƐƚand there 340 
is no imaging modality (or combination of modalities) that is without significant radiation exposure 341 
and could be used as a comparison, therefore the outcome of the review of biochemistry, clinical 342 
data and MRI imaging by the multidisciplinary team was considered the gold standard to determine 343 
the success of treatment and disease free-status. Finally, although two of the patients we describe 344 
(patients 8 and 13) have typical radiological features of sPGLs, their biochemistry was normal and 345 
they have declined surgery, and thus we do not have histological confirmation for them.  346 
 347 
To our knowledge this is the first report of longitudinal screening in patients with SDHx mutations 348 
using non-contrast rapid sequence MRI.  Our data support the use of this technique in the 349 
surveillance of these patients to detect new tumours and monitor size of existing tumours, and 350 
provide evidence that biannual imaging with annual biochemical testing is an effective approach.  351 
 352 
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Figure legend 496 
Figure 1:  497 
(1a) A 20mm lesion medial to the left adrenal gland shown in a coronal T2 haste sequence (Patient 6, 498 
noradrenaline-secreting abdominal paraganglioma).  499 
(1b) A 27mm soft tissue lesion posterior to the pulmonary artery within the mediastinum shown in 500 
an axial gradient-echo T1 weighted sequence (Patient 9, noradrenaline-secreting thoracic 501 
paraganglioma) 502 
(1c) Transverse gradient echo T1 sequence showing bilateral homogenous carotid body tumours at 503 
the bifurcation of the common carotid between the internal and external carotids and (1d) Axial T2 504 
haste sequence showing extensive destructive high signal tumour centered at the right foramen 505 
jugulare (Patient 15, glomus jugulare and bilateral carotid body tumours) 506 
(1e) Well-defined homogeneous soft tissue mass centered at the foramen jugulare shown in an axial 507 
gradient-echo T1 weighted sequence (Patient 3, noradrenaline-producing glomus jugulare). 508 
 509 
Figure 2: Flow diagram of patient surveillance 510 
 511 
 512 
 513 
 514 
 515 
 516 
 517 
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Tables  519 
 520 
Table 1. Characteristics of patients with SDHx subunit mutations 521 
 
SDHB SDHC SDHD 
Number of patients (females) 36 (18) 6 (5) 9 (4) 
Index cases  9 1 3 
Relatives 27 5 6 
Age at the end of screening, mean +/- SD
1 
46.9 +/- 17.6 42.3 +/- 24.4 54.9 +/- 10.6 
Age range 18-76 20-75 26-64 
Index cases: age range at presentation  15-50 37 12-40 
Mean age at first tumour
1 
(range) 36.1 (15-70) 48.5 (37-60) 33.3 (22-56) 
Mean duration of screening in years (range) 6.5 (3.0-10) 4.8 (3.2-10) 5.6 (2.8-10) 
Number of patients who developed tumours in total 11 2 6 
% of patients who developed tumours 31% 33% 67% 
Patients who were diagnosed with tumours on 
surveillance programme 
4 2 3 
Total number of tumours 13 3 13 
HNPGL (functioning) 1 (1) 2 (1) 12 (0) 
sPGL (functioning) 12 (10) 1 (0) 0 
Phaeochromocytoma 0 0 1 
 
1
No statistical difference between the SDHB, SDHC and SDHD groups
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 523 
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 528 
 529 
 530 
 531 
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Table 3. The results of additional imaging tests used to investigate positive screening results during 
monitoring 
 Number of scans Results 
Neck USS 15 12 positive (HNPGLs) 
3 negative (lymph nodes, thyroglossal cyst) 
   
MIBG 4 2 positive 
Patient 6: NA-secreting sPGL  
Patient 10: non-secreting metastatic PGL  
 
2 negative 
Patient 9: NA-secreting thoracic sPGL and a HNGPL 
Patient 18: non-secreting multiple HNGPL 
   
18
FDG PET CT 8 3 positive  
Patient 11: NA-secreting sPGL 
Patient 13: extensive HNPGL  
Patient 21: incidental bone lesion  
 
5 negative  
Patient 2: incidental hilar mass  
Patient 7: non-secreting thoracic sPGL 
Patient 8: sPGL  
Patient 22: lymphangioma 
Patient 23: incidental lymphadenopathy 
 
 533 
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Table 2. List of patients with SDHx subunit mutations who developed tumours with characteristics of disease and treatment 
 
Patient           Mutation Age Tumours Secretion Recurrent/ Multiple or 
Metastatic  
Size of tumour 
(cm)
#
 
Treatment 
1 
+ 
 SDHB  c.72+1G>T 15 Pelvic sPGL NA No (4.0) Excision 
2 
++ 
 SDHB  c.600G>T 17 
24 
Pelvic sPGL 
Abdominal sPGL 
NA- both Multiple (n=2) (NK) 
2.4 
Excision (both) 
 
3 
+ 
 SDHB  exon 1 deletion  50 HNPGL (GJ) NA Locally aggressive 3.9 g-knife radiosurgery 
4 
+
  SDHB  c.137G>A 31 Abdominal sPGL NA and DA No (7.0) Excision 
5 
+ 
 SDHB  c.379dupA 25 Abdominal sPGL NA and DA No (5.0) Excision 
6 
++
  SDHB  c.379dupA 22 
24 
Abdominal sPGL 
Abdominal sPGL 
NA-both Multiple (n=2) (NK) 
2.0 
Excision (both) 
7  SDHB  c.379dupA 20 Thoracic sPGL No No 2.4 Excision 
8  SDHB  c.379dupA 68 Thoracic sPGL* No No 1.2 Monitoring for 7 years, no change 
9 
+ 
 SDHB  c.380T>G 44 Thoracic sPGL NA No 3.7 Monitoring (patient preference) 
10 
+ 
 SDHB  c.17_42dup26 35 Thoracic sPGL No Metastatic (liver spine) 8.3 I
131
 MIBG, Radiotherapy, sunitanib 
11 
+ 
 SDHB  c.17_42dup26 70 Abdominal sPGL NA No (5.0) Excision  
12 
++
 SDHC  c.397C>T 37 
69 
HNPGL (GJ) 
Recurrence of HNPGL 
DA 
DA 
Locally aggressive, 
progressive disease 
>5.3 Sub-total excision, excision or recurrence, g-knife 
radiosurgery  
13  SDHC  c.397C>T 60 HNPGL 
Thoracic sPGL* 
No-both Multiple (n=2) 2.2
 
2.1 
HNPGL: Excision 
sPGL: Monitoring-mild increase in 5 years 
14 
+ 
 SDHD  c.342T>A 40 HNPGLs (bilateral CB)  
HNPGL (GJ) 
No-both Multiple (n=3) R: (NK), L: 1.8
  
1.5 
Right CB: excision, Left CB: monitoring 
GJ: Monitoring, g-knife radiosurgery 
15  SDHD  c.242C>T 12 HNPGL (GJ) 
HNPGLs (bilateral CB) 
No Recurrent, multiple (n=3) 3.5  
R: 2.2, L: 2.7 
GJ: Excision, g-knife radiosurgery 
CB: Monitoring 
16 
+
 SDHD  c.242C>T 22 HNPGL (GJ) 
HNPGL (CB) 
No Recurrent, multiple (n=2), 
locally aggressive (GJ) 
(NK) 
(NK)  
GJ: Excision, g-knife radiosurgery 
CB: Excision 
17  SDHD  c.242C>T  31 HNPGLs (bilateral CB) No Recurrent, multiple (n=2) R: 1.8, L: 1.0 Right: excision 
Left: monitoring 
18  SDHD  c.242C>T 56 HNPGLs (bilateral CB) No Multiple (n=2) R: 3.0, L: 0.6 Right: excision  
Left: monitoring 
+ Index case; ++ Index case with second tumour; * sPGL on imaging, no histology; # maximum diameter by rapid sequence MRI (maximum diameter by diagnostic imaging); NK: 
not known; R: right; L: left; GJ:  glomus jugulare; CB: carotid body tumour, NA: noradrenaline; DA: dopamine 
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